{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:36:38Z","timestamp":1792193798550,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.ygyno.2009.10.047","type":"journal-article","created":{"date-parts":[[2009,11,8]],"date-time":"2009-11-08T09:07:07Z","timestamp":1257671227000},"page":"364-369","source":"Crossref","is-referenced-by-count":23,"title":["Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer"],"prefix":"10.1016","volume":"116","author":[{"given":"K.K.","family":"Shih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.R.","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"M.M.","family":"Leitao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2009.10.047_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2009.10.047_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/gyno.1998.4955","article-title":"Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study","volume":"69","author":"Eisenkop","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib3","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib4","first-page":"101","article-title":"Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma","volume":"42","author":"Griffiths","year":"1975","journal-title":"Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.ygyno.2009.10.047_bib5","first-page":"413","article-title":"Primary cytoreductive surgery for epithelial ovarian cancer","volume":"61","author":"Hacker","year":"1983","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.1988.6.6.983","article-title":"The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma","volume":"6","author":"Piver","year":"1988","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0090-8258(92)90100-W","article-title":"The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"47","author":"Hoskins","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/S0002-9378(94)70090-7","article-title":"The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma","volume":"170","author":"Hoskins","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib10","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1200\/JCO.2007.11.0932","article-title":"Role of surgery in ovarian carcinoma","volume":"25","author":"Fader","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2006.03.051","article-title":"What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?","volume":"103","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0090-8258(89)90593-3","article-title":"Secondary cytoreductive surgery in epithelial ovarian cancer: nonresponders to first-line therapy","volume":"33","author":"Morris","year":"1989","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0090-8258(89)90168-6","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"34","author":"Morris","year":"1989","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.1993.11.3.434","article-title":"Secondary cytoreduction for ovarian cancer following cisplatin therapy","volume":"11","author":"Segna","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib15","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/1097-0142(19951101)76:9<1606::AID-CNCR2820760917>3.0.CO;2-H","article-title":"Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study","volume":"76","author":"Eisenkop","year":"1995","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.10.047_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1006\/gyno.1995.1099","article-title":"Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response","volume":"57","author":"Vaccarello","year":"1995","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X","article-title":"The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma","volume":"88","author":"Eisenkop","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.10.047_bib18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1006\/gyno.2000.5992","article-title":"Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer","volume":"79","author":"Gadducci","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/ejso.2000.1007","article-title":"Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer","volume":"26","author":"Zang","year":"2000","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0029-7844(02)01977-4","article-title":"Secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"99","author":"Tay","year":"2002","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2004.11.057","article-title":"The role of secondary cytoreductive surgery for recurrent ovarian cancer","volume":"97","author":"Gungor","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib22","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.10.047_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2009.10.047_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdn591","article-title":"The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer","author":"Oksefjell","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2004.07.033","article-title":"Tertiary cytoreduction in patients with recurrent ovarian carcinoma","volume":"95","author":"Leitao","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2006.08.037","article-title":"Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome","volume":"104","author":"Karam","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2009.10.047_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)90001-8","article-title":"FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology","volume":"70","author":"Benedet","year":"2000","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2009.10.047_bib28","first-page":"189","article-title":"Survival of patients following secondary cytoreductive surgery in ovarian cancer","volume":"61","author":"Berek","year":"1983","journal-title":"Obstet. Gynecol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809008002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825809008002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T18:29:25Z","timestamp":1558636165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825809008002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0090825809008002"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2009.10.047","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}